NCT01756248View on ClinicalTrials.gov

EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

CompletedOBSERVATIONAL
Enrollment

3,872

Participants

Timeline

Start Date

December 26, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

May 20, 2019

Conditions
Macular Degeneration
Interventions
DRUG

Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)

Patients treated with EYLEA under practical manner for AMD.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY

NCT01756248 - EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan | Biotech Hunter | Biotech Hunter